Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 29130586.
- Also identified by DOI 10.1002/hed.24967.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Fluorine-18 fluorodeoxyglucose positron emission tomography/CT (<sup>18</sup> F-FDG PET/CT) has been widely accepted as an effective method for detecting recurrent papillary thyroid cancer (PTC) in patients with increased serum thyroglobulin (Tg) or Tg antibody (TgAb) levels and negative whole-body scintigraphy (WBS) results. The role of WBS as a diagnostic tool in detecting recurrence has relatively decreased recently. However, only a few studies have examined the usefulness of <sup>18</sup> F-FDG PET/CT for evaluating patients with recurrent PTC, regardless of the WBS results. The purpose of this analysis was to evaluate the diagnostic value and prognostic role of <sup>18</sup> F-FDG PET/CT for patients with recurrent PTC, irrespective of their WBS results. Sixty-six patients with locoregional recurrent PTC who underwent <sup>18</sup> F-FDG PET/CT and neck CT within 6 months before surgical treatment were included in this retrospective analysis. Imaging findings were compared with postoperative histopathologic results. The diagnostic values of <sup>18</sup> F-FDG PET/CT and neck CT were compared according to the serum Tg and TgAb levels and cervical levels. Each patient's status at the last follow-up was also reviewed, and survival probabilities were estimated using the Kaplan-Meier plot. The sensitivity, specificity, and diagnostic accuracy of <sup>18</sup> F-FDG PET/CT for the entire patient group were 38.5%, 90.2%, and 58.3%, respectively. The corresponding neck CT values were 55.0%, 85.7%, and 66.7%, respectively. According to the serum Tg and TgAb levels, except for the specificity, most diagnostic values of <sup>18</sup> F-FDG PET/CT were worse than those of the neck CTs, with or without statistical significance. For the high maximum standardized uptake value (SUVmax) group (SUVmax >10) and the low SUVmax group, the median locoregional disease-free survival times were 33.3 months and 81.8 months, respectively (P < .001). The diagnostic value of <sup>18</sup> F-FDG PET/CT for localizing recurrent lesions was worse than that of the neck CT, irrespective of the WBS results. However, patients with a higher SUVmax showed a significantly worse prognosis than did those with a lower SUVmax. Therefore, we suggest that, in patients with recurrent PTC, <sup>18</sup> F-FDG PET/CT should be considered for prognostication rather than diagnosis.
Medical subject headings
- Carcinoma, Papillary
- Fluorodeoxyglucose F18
- Neoplasm Recurrence, Local
- Positron Emission Tomography Computed Tomography
- Thyroid Neoplasms
- Tomography, X-Ray Computed